You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Although the benefit seen in the CAVE study needs Phase III confirmation, the analysis showed that plasma ctDNA testing may help identify best responders.
Encorafenib (Pfizer/Array BioPharma's Braftovi) is approved in combination with cetuximab (Eli Lilly's Erbitux) for previously treated patients.
A new study suggests that colorectal cancers increase their mutation rate to dodge treatment in a manner that mirrors microbial resistance mechanisms.
In a study, patients with class 3 BRAF mutations were more likely to respond to an anti-EGFR antibody treatment as a first-or second-line therapy.
An international team saw an overall survival benefit when using BRAF, MEK, and EGFR inhibitors together in previously treated, BRAF-mutated metastatic colorectal cancer patients.
Keytruda and Ibrance demonstrate activity in molecularly defined populations, while a new cohort will explore Gilotrif in tumors with NRG1 fusions.
The company is developing a companion diagnostic to identify head and neck cancer patients most likely to benefit from Erbitux.
The results confirmed that circulating mutations can be reliably detected and changed during treatment, and showed that they could be a valuable prognostic biomarker.
Results from a recent study clarify some conflicting prior determinations, and provide a new rationale to further explore the FCGR2A biomarker in prospective trials.